Bioequivalence and Bioavailability Forum

There isn't any biological background that might explain this issue? Or problems during manufacturing? This is really awkward... the CI and point estimate are far more "perfect" than I am used to see. In fact, in full replicate studies, I've seen reference drugs "performing" poorly when compared with single administrations of themselves... Is the dose-toxicity so sensible for this drug that event the narrower limits does not apply in this case? Did a quick search and haven't find any study reporting the dose-response of this drug